
The 10th ECIL meeting updated prophylaxis strategies for invasive fungal diseases. Isavuconazole, micafungin, and caspofungin received B-II grades for AML/MDS patients. Posaconazole is now supported for high-risk MDS on azacytidine. CAR-T recipients are addressed for the first time, with mold-active prophylaxis recommended in high-risk patients. Pediatric guidelines now include caspofungin (B-I) and expanded prophylaxis for older ALL patients.
Like
Save
Share